M&A

M&A

Eris Lifesciences to acquire remaining 30% in Swiss Parenterals for Rs.423-Cr

BSE Announcement   Business Standard  

Mumbai-headquartered, publicly listed Eris Lifesciences Ltd is to acquire the remaining 30% stake in Ahmedabad-headquartered Swiss Parenterals Ltd (SPL) for INR 423.3 crore through a share swap. Post acquisition, SPL will become a wholly-owned subsidiary of Eris.SPL acts as a contract development and manufacturing organisation (CDMO) for a wide range of products, including prescription and over-the-counter (OTC) drugs, dietary supplements, and cosmetics. It reported a turnover of INR 351.11 crore in FY25.

In Feb 2024, Eris Lifesciences acquired a 51% stake in SPL for INR 637.50 crore.